Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2)

• 主要な著者: Paolo Gisondi (著者), Alice B. Gottlieb (著者), Boni Elewski (著者), Matthias Augustin (著者), Sandy McBride (著者), Tsen-Fang Tsai (著者), Christine de la Loge (著者), Frederik Fierens (著者), José M. López Pinto (著者), Nicola Tilt (著者), Mark Lebwohl (著者)
• フォーマット: 図書
• 出版事項: Adis, Springer Healthcare, 2022-12-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract Introduction Certolizumab pegol (CZP) is an Fc-free, PEGylated, anti-tumour necrosis factor biologic. Safety and efficacy data for CZP over 3 years have been previously reported. We report 3-year quality of life (QoL) outcomes for patients treated with CZP, pooled from two phase 3 trials. M...